Navigation Links
Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
Date:7/31/2008

-- This Approval Creates New Growth Opportunities for the Company -- Company Expects to Exceed Its FY2008 Make Good Target of $5.6 million

CHENGDU, China, July 31 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc. (OTC Bulletin Board: TYNP), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that it has received approval from the Chinese State Food and Drug Administration (SFDA) to produce Simvastatin Tablets (SFDA approval number H20083478).

Simvastatin is a Statin drug which is used to control hypercholesterolemia and treat coronary heart diseases. This is the only Statin type drug approved by SFDA to treat these conditions and is highly effective, with fewer side effects when compared to other similar drugs. Simvastatin can reduce the mortality rate of coronary heart diseases, coronary artery diseases, and cerebral stroke by 17%, 24% and 25%, respectively. The China Cholesterol Education Program recommends Simvastatin to treat these conditions. Simvastatin is also listed in the National Medical Insurance Program, thus allowing insured patients to receive reimbursement for the costs of this prescription.

Research report from Tulane University published on American Heart Association's Journal of Circulation shows that due to lifestyle changes in China, high levels of hypercholesterolemia and low levels of awareness, treatment, and information regarding same has made cardiovascular disease the leading cause of death in China. As a leading Statin class drug, Simvastatin had total sales of over $190 million in China during 2006. Less than 40% of Simvastatin sold in China's market is produced by domestic manufacturers. Simvastatin Tablets from Tianyin are expected to gain large market share from companies that currently import Simvastatin due to Tianyin's competitive pricing advantages.

Tianyin's Simvastatin Tablets are sold by prescription in hospitals, which is the major sales channel for drugs in China. Tianyin will start producing Simvastatin Tablets in early August, while selling it through our strategic distributor partners throughout China.

"We are very pleased to receive approval of Simvastatin from the Chinese SFDA, a very important step and positive progress for our business which further diversifies and complements our product portfolio," Dr. Jiang, Chairman and CEO of Tianyin Pharmaceutical Co., Inc., commented. "This favorable decision by the SFDA provides further evidence of our ability to get drugs through the approval process and to market. We are optimistic that the additional drugs that are currently in our development pipeline for SFDA approval will be able to move through this process toward commercialization."

"We are well positioned to take advantage of this new growth opportunity. This approval will enable us to immediately leverage our production capacity and distribution network to facilitate commercialization of this new drug. We expect to begin production of record revenues of Simvastatin Tablets by August 2008 and currently maintain the capacity to produce approximately $2 million of this product annually. The margin profile is anticipated to be slightly better than our current product mix. We will be announcing our June 30, 2008 year end earnings date in the near term but we would like to reiterate that the company expects to exceed its FY2008 make good of $5.6 million in net income or fully diluted EPS of $0.16 per share," concluded Dr. Jiang.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 34 modernized TCMs in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 51 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,187 employees. Tianyin achieved revenue of $20.4 million and net income of $3.95 million in FY2007 ending June 30, 2007. For more information about Tianyin Pharmaceuticals, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please contact:

For the Company:

Allen Tang, Ph.D., MBA, Assistant to the CEO

China

Tel: +86-158-2122-5642

Email: Allen.y.tang@gmail.com

Investors:

HC International, Inc.

Alan Sheinwald

US

Tel: +1-914-669-0222

Email: Alan.Sheinwald@hcinternational.net


'/>"/>
SOURCE Tianyin Pharmaceutical, Co., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
2. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
4. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
5. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
6. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
7. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: